\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ steroid\\ therapy\\ for\\ symptomatic\\ or\\ progressive\\ disease\\.\ \(0\)\
\-\ bilateral\\ hilar\\ adenopathy\\ and\\ reticular\\ interstitial\\ disease\\.\\ \\ expected\\ postoperative\\ median\\ sternotomy\\ changes\\.\ \(0\)\
\-\ sarcoid\ \(163\)\
\-\ sarcoid\ \(163\)\
\-\ lymphoma\ \(373\)\
\-\ infectious\\ etiology\ \(7\)\
\-\ 63\\ year\\ male\\ with\\ 5\\ year\\ history\\ of\\ sarcoid\\,\\ asymptomatic\ \(1\)\
\-\ this\\ is\\ an\\ atypical\\ presentation\\ due\\ to\\ the\\ patient\\'s\\ age\\.\\ however\\,\\ he\\ is\\ largely\\ asymptomatic\\ as\\ are\\ approximately\\ 50\\ \\%\\ of\\ people\\ who\\ are\\ diagnosed\\ incidentaly\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarcoid\\:\\ 0\\.4636471268989011\ \(0\)\
\-\ incidentaly\\:\\ 0\\.25182676532140735\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.2243761365218872\ \(0\)\
\-\ sternotomy\\:\\ 0\\.1970209146487798\ \(0\)\
\-\ people\\:\\ 0\\.1917538318624206\ \(0\)\
\-\ reticular\\:\\ 0\\.1883512007608665\ \(0\)\
\-\ largely\\:\\ 0\\.1883512007608665\ \(0\)\
\-\ postoperative\\:\\ 0\\.17113385064932748\ \(0\)\
\-\ median\\:\\ 0\\.17055021515486857\ \(0\)\
\-\ 63\\:\\ 0\\.159224521318308\ \(0\)\
\-\ steroid\\:\\ 0\\.15883674402759373\ \(0\)\
\-\ hilar\\:\\ 0\\.1511095394963319\ \(0\)\
\-\ interstitial\\:\\ 0\\.14939285782373046\ \(0\)\
\-\ expected\\:\\ 0\\.1485713150383337\ \(0\)\
\-\ adenopathy\\:\\ 0\\.13862047885011447\ \(0\)\
\-\ disease\\:\\ 0\\.1383486799554245\ \(0\)\
\-\ atypical\\:\\ 0\\.13519659804227116\ \(0\)\
\-\ etiology\\:\\ 0\\.13275382182439677\ \(0\)\
\-\ infectious\\:\\ 0\\.13259808573620224\ \(0\)\
\-\ symptomatic\\:\\ 0\\.12671632073085096\ \(0\)\
\-\ progressive\\:\\ 0\\.12621389112091735\ \(0\)\
\-\ are\\:\\ 0\\.12506306546500545\ \(0\)\
\-\ diagnosed\\:\\ 0\\.11937175721606146\ \(0\)\
\-\ 50\\:\\ 0\\.11508744402536385\ \(0\)\
\-\ presentation\\:\\ 0\\.11344090303254736\ \(0\)\
\-\ available\\:\\ 0\\.11180744385641564\ \(0\)\
\-\ approximately\\:\\ 0\\.10515007615234305\ \(0\)\
\-\ age\\:\\ 0\\.10345881576200072\ \(0\)\
\-\ year\\:\\ 0\\.10157205260720635\ \(0\)\
\-\ changes\\:\\ 0\\.09959415101579192\ \(0\)\
\-\ lymphoma\\:\\ 0\\.09814456729267867\ \(0\)\
\-\ he\\:\\ 0\\.09758450501405054\ \(0\)\
\-\ however\\:\\ 0\\.09753831959350572\ \(0\)\
\-\ due\\:\\ 0\\.09472623139356597\ \(0\)\
\-\ therapy\\:\\ 0\\.09468439362463495\ \(0\)\
\-\ who\\:\\ 0\\.09321721928425131\ \(0\)\
\-\ is\\:\\ 0\\.09025948651905841\ \(0\)\
\-\ bilateral\\:\\ 0\\.08856595815845916\ \(0\)\
\-\ male\\:\\ 0\\.07337228143576253\ \(0\)\
\-\ as\\:\\ 0\\.06620328557046061\ \(0\)\
\-\ not\\:\\ 0\\.06505644374989653\ \(0\)\
\-\ of\\:\\ 0\\.06449860799810232\ \(0\)\
\-\ an\\:\\ 0\\.0630163746586287\ \(0\)\
\-\ history\\:\\ 0\\.06296055053614166\ \(0\)\
\-\ or\\:\\ 0\\.057328627319659875\ \(0\)\
\-\ this\\:\\ 0\\.05662591852182125\ \(0\)\
\-\ patient\\:\\ 0\\.053598962082233984\ \(0\)\
\-\ for\\:\\ 0\\.0499475606410469\ \(0\)\
\-\ to\\:\\ 0\\.041197981621764426\ \(0\)\
\-\ and\\:\\ 0\\.03405250162579505\ \(0\)\
\-\ the\\:\\ 0\\.03288221887738174\ \(0\)\
\-\ with\\:\\ 0\\.03226857295050601\ \(0\)\
